Furthermore, K–M survival analysis in three independent immunotherapy cohorts, including IMvigor210 (urothelial carcinoma), GSE126044 (non-small cell lung cancer), and GSE135222 (melanoma and lung cancer), consistently revealed that patients with low KLF5 expression exhibited improved survival outcomes following immunotherapy (Figure 7C). This evidence concerns the gene KLF5 and urothelial carcinoma.